Abstract: PUB087
Safety and Efficacy of the First Mobile Intelligent Hemodialysis Platform in Mainland China: Protocol for a Single-Center Prospective Exploratory Study in Patients on Maintenance Hemodialysis
Session Information
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Lu, Renhua, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Jin, Haijiao, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Lu, Yifei, Shanghai Jiao Tong University School of Public Health, Shanghai, China
- Zhou, Yijun, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Wu, Wangshu, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Xie, Kewei, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Gu, Leyi, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
Background
Patients with end-stage kidney disease (ESKD) rely on maintenance hemodialysis (MHD) treatment, but traditional center-based dialysis models face challenges in accessibility and flexibility. While mobile dialysis units have shown promise internationally, no implementation studies have been reported in mainland China. Additionally, existing mobile solutions rarely incorporate advanced healthcare technologies for real-time monitoring and intelligent decision support.
Methods
This prospective, single-center, exploratory clinical trial will enroll 20 adult patients (aged 18-75 years) with ESKD who have been receiving MHD treatment. Participants will receive a single 4-hour hemodialysis session on a mobile intelligent dialysis platform equipped with comprehensive dialysis facilities, real-time monitoring systems, and artificial intelligence-driven clinical decision support. The mobile intelligent hemodialysis platform is a specialized medical vehicle integrating comprehensive dialysis capabilities through six strategically arranged functional zones as illustrated in Figure 1.
Results
The primary endpoint is the successful completion rate of hemodialysis sessions. Secondary endpoints include measures of dialysis adequacy, hemodynamic stability during treatment, changes in key biochemical parameters and quality of life scores. Safety assessments will comprise documentation of adverse events and severe adverse event.
Conclusion
This study represents the first evaluation of a mobile intelligent hemodialysis platform in mainland China, integrating traditional dialysis equipment with advanced smart healthcare systems. The platform will demonstrate potential to safely deliver standard hemodialysis treatment with adequate dialysis outcomes while maintaining hemodynamic stability.
Figure1. Schematic Layout of the Mobile Intelligent Hemodialysis Platform With Functional Zones and Key Medical Components.
Funding
- Commercial Support – Guoxin Wang'an (Shanghai) Big Data Technology Co., Ltd.